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Eosinophilic esophagitis (EoE) is a clinicopathologic condition of
increasing recognition and prevalence. In 2007, a consensus
recommendation provided clinical and histopathologic
disorder. Practice patterns inmultiple subspecialties (adult and pe-
diatric gastroenterology, allergy/immunology, pulmonary medi-
cine, and otolaryngology) have begun to include EoE in the
clinical evaluation, endoscopy, histopathology, genetics, allergy,
Abbreviations used
APT: Atopy patch test
CR: Consensus recommendation
EoE: Eosinophilic esophagitis
GERD: Gastroesophageal reflux disease
hpf: High-power field
PPI: Proton pump inhibitor
SPT: Skin prick test
TSLP: Thymic stromal lymphopoietin
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4 LIACOURAS ET ALguidance for the diagnosis and treatment of EoE; however, only
a minority of physicians use the 2007 guidelines, which require
fulfillment of both histologic and clinical features. Since 2007,
the number of EoE publications has doubled, providing new
disease insight. Accordingly, a panel of 33 physicians with
expertise in pediatric and adult allergy/immunology,
gastroenterology, and pathology conducted a systematic review
of the EoE literature (since September 2006) using electronic
databases. Based on the literature review and expertise of the
panel, information and recommendations were provided in each
of the following areas of EoE: diagnostics, genetics, allergy
testing, therapeutics, and disease complications. Because
accumulating animal and human data have provided evidence
that EoE appears to be an antigen-driven immunologic process
that involves multiple pathogenic pathways, a new conceptual
definition is proposed highlighting that EoE represents a
chronic, immune/antigen-mediated disease characterized
clinically by symptoms related to esophageal dysfunction and
histologically by eosinophil-predominant inflammation. The
diagnostic guidelines continue to define EoE as an isolated
chronic disorder of the esophagus diagnosed by the need of both
clinical and pathologic features. Patients commonly have high
rates of concurrent allergic diatheses, especially food
sensitization, compared with the general population. Proved
therapeutic options include chronic dietary elimination, topical
corticosteroids, and esophageal dilation. Important additions
since 2007 include genetic underpinnings that implicate EoE
susceptibility caused by polymorphisms in the thymic stromal
lymphopoietin protein gene and the description of a new
potential disease phenotype, proton pump inhibitor-responsive
esophageal eosinophila. Further advances and controversies
regarding diagnostic methods, surrogate disease markers,
allergy testing, and treatment approaches are discussed.
(J Allergy Clin Immunol 2011;128:3-20.)
Key words: Eosinophils, eosinophilic, esophagitis, esophageal,
food allergy
Discuss this article on the JACI Journal Club blog: www.
jaci-online.blogspot.com.
Since the publication of the eosinophilic esophagitis (EoE)
consensus recommendation (CR) in 2007,1 scientific publications
focusing on EoE have nearly doubled, and the recognition of
patients who have eosinophil-predominant esophagitis has in-
creased dramatically. Early studies described aspects of the condi-
tion in children, but it has become clear that adults have a similar
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doi:10.1016/j.jaci.2011.02.040differential diagnosis of various clinical presentations. Increased
recognition, along with the chronic nature of EoE, has led to a
steady increase in prevalence.
A salient aspect of the 2007 CR was that EoE was defined as a
clinicopathologic entity in which esophageal eosinophilia was a
necessary but not sufficient criterion for diagnosis. Most recent
publications pertaining to EoE, however, have included cohorts
of patients in whom the diagnosis was based solely on the
histologic finding of esophageal eosinophilia. In fact, a recent
study and a 2010 survey of 1836 physician members of the
American College of Gastroenterology, the American Academy
of Allergy, Asthma & Immunology, and the North American
Society of Pediatric Gastroenterology, Hepatology, and Nutrition
identified that only one third of respondents used the CR
definition.2,3 Furthermore, the 2007 CR statements regarding
the clinical presentation, pathogenesis, treatment, and complica-
tions have elucidated ambiguities and controversy in the context
of expanding clinical experience and increased scientific
investigation.
To address these concerns, an interdisciplinary expert panel
was convened with the following goals: (1) to provide clarity to
the definition, nomenclature, clinical presentation, histology, and
diagnostic testing; (2) to report onvarious disease phenotypes that
might exist; (3) to evaluate allergic manifestations and allergy
tests related to antigenic causes of the disease; (4) to review,
reassess, and provide recommendations on dietary and medical
treatments; and (5) to review the use of esophageal dilation and
complications associated with EoE. The interdisciplinary panel
subsequently generated this report with the hope that the follow-
ing information will provide a framework to improve care and
develop future studies on EoE.
METHODOLOGY
A task force of 33 physicians with recognized expertise in theand treatment of EoE was gathered to address specific clinically
relevant topics. The expert panel consisted of pediatric and adult
gastroenterologists, allergists, and pathologists. A systematic
review of the English-language medical literature between
September 2006 and August 2010 was performed by using
electronic databases (MEDLINE, PubMed, and Ovid). Relevant
data were discussed among committee members in a series of
conference calls. Critical evaluations included study design,
numbers of patients, definitions used, outcomes reported, and
potential biases. The chair of each committee synthesized the
data, and inconsistencies were resolved by means of discussion
until a consensus was achieved. The recommendations of each
committee included a review and update of the 2007 Consensus
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research. The manuscript was reviewed and approved by all 33
participants.
REVIEW OF 2007 CR AND GUIDELINES
The original 2007 consensus definition of EoE, based on botha threshold number of eosinophils and clinical parameters of
CONCEPTUAL DEFINITION AND DIAGNOSTIC
GUIDELINES FOR EoE
Proposed conceptual definition of EoE
Pemphigoid vegetans
Connective tissue disease
Graft-versus-host diseaseupper intestinal symptoms for which gastroesophageal reflux
disease (GERD) was not the underlying cause, might have been
problematic. First, the histologic finding of 15 or more eosino-
phils per high-power field (hpf) in an esophageal biopsy spec-
imen carries no proved biological significance or power to
discriminate among various esophageal diseases. Second, the
exhortation to eliminate GERD as a potential cause of esopha-
geal eosinophilia (as determined by best clinical practice, which
can include either failure of proton pump inhibitors [PPIs] to
resolve symptoms and ongoing eosinophilia or a normal pH
impedance monitoring study) has not been rigorously applied or
validated.
The reasons for this are multiple and relate, in part, to the
identification of at least 2 groups of patients with eosinophil-
predominant esophageal inflammation. One group, best described
as having GERD with more eosinophils than usual, has abnormal
pHmonitoring results and a clinicopathologic response to PPIs.4,5
Another group, best described as having PPI-responsive esopha-
geal eosinophilia, has normal pH study results but nevertheless
shows a clinicopathologic response to proton pump inhibition.6
Whether this latter group represents GERD that was not identified
by means of pH impedance–monitoring studies* or a clinical re-
sponse to the potential anti-inflammatory properties of PPIs is
not yet certain. In neither of these groups has an association
with an antigenic or immunologic cause of esophageal eosino-
philia been thoroughly studied.
Another inherent problem was the use of the abbreviation
‘‘EE.’’ Although easily understood by allergists and pathologists,
among gastroenterologists EE classically defines ‘‘erosive esoph-
agitis.’’ The use of the abbreviation EoE rather than EE for EoE
should eliminate the potential for this confusion.
No studies have been published since the CR that would clearly
permit diagnosis or phenotype discrimination based on pathogno-
monic clinical/histologic features or biomarkers. Thus although
many studies performed since 2007 have used the 2007 CR as
proposed, the majority do not, leaving diagnostic uncertainty both
for patients and within the published literature.7 Because of the in-
creasing recognition of patients with esophageal eosinophilia and
the clinical demand for a more relevant diagnostic guideline, an ur-
gent need has developed to revise the previously published CR.8-10
*pH testing can be done with a transnasal tube with a pH sensor at its tip, where the tip is
placed 5 cm above the manometrically determined proximal border of the lower
esophageal sphincter, or can be done with a wireless pH capsule that is pinned 6 cm
above the squamocolumnar junction at endoscopy. Both systems capture pH record-ings to measure the percentage of total time that an acidic pH (<4.0) is present in the
distal esophagus, along with other measurements. Recorders have patient-activated
buttons to indicate symptoms, meals, and posture (upright or supine). Thus these
devices can be used to measure the temporal relation between the patients’ recorded
symptoms and acid reflux. Complimenting pH technology is the advent of impedance.
Impedance monitors act like motion detectors and show the direction of flow not only
of acidic liquids, but also of gas, and liquid of any pH (weakly acidic, neutral, or basic).Recognition of the differences between esophageal eosino-
philia as a histologic descriptor and EoE as a disease, in itself, is
critical (Table I). As clinical experience has developed and as
more patients are being identified, varying phenotypes based on
symptoms or anatomic abnormalities (eg, stricturing) might de-
fine a ‘‘spectrum’’ of EoE. As supported by a number of past
and recent basic/translational studies and clinical experience
demonstrating that the underlying cause of EoE is likely an aber-
rant ‘‘immune’’ or ‘‘antigenic’’ response associated with consis-
tent endoscopic, histologic, and genetic abnormalities, a
conceptual definition for EoE is proposed.11-45 Use of this con-
ceptual definition not only will provide a framework to refine
our perceptions and hypotheses but alsowill guide future diagnos-
tic tests, therapeutic modalities, and pathogenetic studies on EoE.
Conceptual definition
Eosinophilic esophagitis represents a chronic, immune/
antigen-mediated esophageal disease characterized clinically by
symptoms related to esophageal dysfunction and histologically
by eosinophil-predominant inflammation.
Proposed diagnostic guideline for EoE
In conjunction with this conceptual definition of EoE, recent
clinical experience and research supports revisions in the original
diagnostic guidelines for EoE. Rationales for statements in the
current guidelines comparedwith the 2007CRare listed inTable II.
Diagnostic guideline
EoE is a clinicopathologic disease. Clinically, EoE is
characterized by symptoms related to esophageal dysfunction.
Pathologically, 1 or more biopsy specimens must show
eosinophil-predominant inflammation. With few exceptions, 15
eosinophils/hpf (peak value) is considered a minimum threshold
for a diagnosis of EoE. The disease is isolated to the esophagus,
and other causes of esophageal eosinophilia should be excluded,
specifically PPI-responsive esophageal eosinophilia. The disease
should remit with treatments of dietary exclusion, topical corti-
costeroids, or both. EoE should be diagnosed by clinicians, taking
into consideration all clinical and pathologic information; neither
of these parameters should be interpreted in isolation.
For optimal pathologic evaluation, multiple biopsy specimens
from the proximal and distal esophagus should be obtained and
evaluated for a variety of pathologic features. Pathologists should
decades of life; however, EoE can occur at any age.48,49 EoE oc-
curs in most racial and ethnic groups, although many studies have
reported predominance in non-Hispanic whites; the reason for
50-54
TABLE II. Rationale for definition of and diagnostic guidelines for EoE
1. Change in EE abbreviation. EE often has been used as an abbreviation for erosive esophagitis. Use of the abbreviation EoE rather than EE for eosinophilic
esophagitis should eliminate the potential for confusion.
2. Inclusion of the word chronic. Clinical experience supports that EoE is a chronic disease that will require long-term follow-up and treatment.
3. Inclusion of the term immune/antigen driven. An increasing body of clinical, translational, and basic evidence supports a role of an aberrant immune
response (potentially reversible with treatment) as an underlying pathogenetic feature of EoE.
4. Continued use of the word clinicopathologic. No biomarker or pathognomonic element has been identified that would eliminate the need for both
symptoms and an abnormal histology to make the diagnosis.
5. No change in threshold number of 15 eosinophils/hpf. Since the 2007 CR, no studies have identified a clear ‘‘lower limit of esophageal eosinophilia’’ or
threshold number that would define EoE or have identified other histologic features or pattern of disease distribution that are pathognomonic of EoE.
6. No change in the use of hpf as the unit of measurement for eosinophilia. No studies have yet determined a standardized size of an hpf, and this might be
practically unachievable. This issue is problematic because the size of an hpf can alter the reported number of eosinophils per hpf.
7. Inclusion of topical steroids/diet exclusions as a treatment. Current clinical evidence exists to include this paradigm to differentiate EoE from other
diseases. Other potential therapies might exist but have not yet been supported in the literature.
8. Exclusion of GERD reference. A number of other causes of esophageal eosinophilia have been identified, and a broader statement has been included that
allows for clinical discretion to be used.
9. Inclusion of patients with less than 15 eosinophils/hpf. A small number of patients with EoE (and who are treated with a PPI) might have less than the
threshold number of eosinophils on their mucosal biopsy specimens associated with other features of eosinophilic inflammation, including microabscess
formation, superficial layering, or extracellular eosinophil granules. Potential reasons for this finding include but are not limited to inadequate biopsy
specimens, sampling error, chronic disease, or partial treatment response.
10. Inclusion of the term PPI-responsive esophageal eosinophilia. Therapeutic/basic studies and clinical experience have identified a potential anti-
inflammatory or barrier-healing role for proton pump inhibition in patients with esophageal eosinophilia.
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eosinophil value (obtained from the area with the highest density
of eosinophils), eosinophilic microabscesses, surface layering of
eosinophils, extracellular eosinophil granules, basal cell hyper-
plasia, dilated intercellular spaces, and lamina propria fibrosis. In
a few circumstances patients might have strong clinical evidence
for EoE and have less than 15 eosinophils/hpf, with other
histologic features indicative of eosinophilic inflammation.
An emerging body of literature and clinical experience de-
scribes a subset of patients whose symptoms and histopathologic
findings are responsive to PPI treatment and who might or might
not havewell-documented GERD. Until more is known regarding
this subgroup of patients, these patients should be given diagnoses
of PPI-responsive esophageal eosinophilia. Future studies should
be performed to determine whether PPIs help to diminish an
immune/antigen-driven response, as is known to occur in patients
with EoE.
SUMMARY OF LITERATURE SINCE THE 2007 CR
History and physical examination
Update of 2007 recommendations. Several studies haveconfirmed previously described clinical features of EoE, but no
pathognomonic features have been identified. Clinical manifes-
tations of EoE in children are nonspecific and vary by age such
that diagnosis based on symptoms alone is not feasible. Infants
and toddlers often present with feeding difficulties, whereas
school-aged children are more likely to present with vomiting or
pain.46,47 Dysphagia is a predominant symptom in adolescents.
EoE in children is most often present in association with other
manifestations of atopic diathesis (food allergy, asthma, eczema,
chronic rhinitis, and environmental allergies) and is responsive to
elimination of specific dietary antigens in that population.
The typical patient with EoE is an atopic male (male/female
ratio, 3:1) who presents in childhood or during the third or fourththis requires further investigation. Physical examinations
are useful in children to identify normal growth patterns and in
both children and adults to identify comorbid allergic diseases;
however, no features on physical examination are specific in mak-
ing the diagnosis of EoE. In addition, no oral or pharyngeal man-
ifestations of EoE have been identified, although some children
who have EoE might present with laryngeal symptoms.55
Symptoms in adult patients with EoE are somewhat stereotyp-
ical and include dysphagia, chest pain, food impaction, and upper
abdominal pain. Solid-food dysphagia continues to be the most
common presenting symptom.48,49,56,57 When examining all pa-
tients presenting with dysphagia in endoscopy units, EoE has a
prevalence of up to 15%.56,57 In some series chest pain is the second
leading symptom in adults with EoE.6,58 Whether chest pain from
EoE can be differentiated from GERD or is due to esophageal hy-
persensitivity to acid remains to be determined.6,58,59,60 Food im-
paction necessitating endoscopic bolus removal occurs in 33% to
54% of adults with EoE.61 Upper abdominal pain, symptoms of
GERD, and nonspecific throat symptoms, including globus, have
also been reported in some adults with EoE. Recent clinical obser-
vations suggest that chest discomfort associated with EoE might
have different features than those reported in patients with GERD.
A subgroup of patients has been increasingly recognized who
have (1) a typical EoE symptom presentation, (2) have had GERD
diagnostically excluded, and (3) demonstrated a clinicopathologic
response toPPIs.6,58,59,62,63Termsused todescribe these patients in-
clude PPI-responsive esophageal eosinophilia and PPI-responsive
EoE. The latest term is controversial because limited evidence to
support the effect of PPIs in an ‘‘immune/antigen-driven’’ inflam-
matory response exists. Potential explanations include healing of
a disrupted epithelial barrier to prevent further immune activation,
decreased eosinophil longevity, inherent anti-inflammatory proper-
ties of PPIs, or unreliable diagnostic testing.64-67
Avalidated symptom-assessment tool is not available, such that
recent studies attempting to correlate symptoms with histology
have too little objective basis and have yielded conflicting results.
Some studies found such a correlation,40,49,62,68,69 and others did
not.57,70-72 The correlation of symptom severity with the density
Two studies have provided information on the diagnostic utility
of these endoscopic findings. In one study of 222 patients with
dysphagia who had endoscopy with esophageal biopsy, 33 (15%)
57
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currently insufficient to permit either diagnosis at presentation
or a critical assessment of the efficacy of therapy. The absence
of symptoms in the face of active inflammation is particularly
problematic because it is uncertain whether persistent inflamma-
tion will result in complications such as stricture formation.
Committee clinical recommendations. Any patient with
symptoms suggestive of EoE should undergo a careful history,
with a particular focus on eating and swallowing habits. Both
children and adults with EoE often rapidly adapt eating habits to
manage their impaired esophageal function; a number of these
compensatory behaviors will escape detection unless the clinician
maintains a high index of suspicion (see Table E1 in this article’s
Online Repository at www.jacionline.org).
In children physical examination is essential to assess param-
eters of growth and nutrition that might be affected by the effect of
the disease itself (eg, feeding difficulties that limit intake) or by
attempts at therapy that involve severe dietary restrictions.
Appropriate evaluations should be undertaken when signs indic-
ative of other conditions that might involve the esophagus (eg,
Crohn disease and eosinophilic gastroenteritis) or that might
mimic the condition (eg, GERD and achalasia) are present.
Because an emerging group of patients with PPI-responsive
esophageal eosinophilia has been identified, clinical judgment, as
well as information derived from therapeutic response to PPI, pH
monitoring, or both, should be taken into careful consideration to
distinguish esophagitis related to GERD from that caused by EoE.
PPI responsiveness or diagnostic testing (pH monitoring) might
not adequately distinguish GERD and EoE.
Committee future recommendations. Validated
symptom-assessment tools that can be used to discriminate EoE
from other causes of esophageal eosinophilia and to monitor the
effect of treatments in therapeutic trials are urgently needed.
Studies to identify a reliable biomarker of inflammation will be
required to limit the number of endoscopies needed to confirm
control over the inflammatory process. Additional mechanistic
studies clarifying PPI-responsive esophageal eosinophiliawill aid
in our understanding of the pathogenesis of EoE. In the future
these studies could also use translational methods (eg DNA
microarrays or specific gene and protein levels through immuno-
chemistry, ELISA, or both) to incorporate biologic measures to
further refine the clinical definition of EoE.
Endoscopic and radiologic features
Update of 2007 recommendations. A number of studieshave confirmed the presence of esophageal abnormalities iden-
tifiable by means of endoscopy in patients with EoE, including
fixed esophageal rings (sometimes called corrugated rings or
trachealization), transient esophageal rings (sometimes called
feline folds or felinization), whitish exudates, longitudinal fur-
rows, edema, diffuse esophageal narrowing, narrow-caliber
esophagus, and esophageal lacerations induced by passage of
the endoscope (a manifestation of mucosal fragility that, when
severe, gives the esophagus the appearance of crepe paper).
However, because all of these endoscopic features have been
described in other esophageal disorders, none can be considered
pathognomonic for EoE.had histologic evidence of EoE. Among 21 patients who had en-
doscopic features suggestive of EoE, the diagnosis was confirmed
by means of biopsy in only 8 (38%). Ten (9.8%) of 102 patients
with a normal endoscopic examination had histologic evidence
of EoE. Esophageal eosinophilia was frequently found in patients
who had other causes of dysphagia (eg, reflux esophagitis and
peptic stricture). Another study described similar findings.56
Among 261 patients with dysphagia who had endoscopy with
esophageal biopsy, 31 (12%) had histologic evidence of EoE.
However, only 12 (34%) of 35 patients with esophageal rings
seen on endoscopy were confirmed to have esophageal eosino-
phils on biopsy. The optimal number of mucosal biopsy speci-
mens that should be obtained to maximize the diagnostic yield
of EoE has begun to be addressed.73,74 By using 15 eosinophils/
hpf as a threshold for diagnosis, one study identified a diagnostic
sensitivity of 84%, 97%, and 100% for obtaining 2, 3, and 6 bi-
opsy specimens, respectively.73
Barium contrast radiography can identify a number of the
anatomic andmucosal abnormalities of EoE, but the sensitivity of
radiography as a diagnostic test for this condition appears to be
low. One study found that barium swallow results were normal in
12 of 17 children with EoE, including 4 who had endoscopy for
food impaction.75
Committee clinical recommendations. Endoscopy with
esophageal biopsy remains the only reliable diagnostic test for
EoE. However, the finding of isolated esophageal eosinophilia
without determining corroborating symptoms and ruling out other
causes of esophageal eosinophilia is inadequate to make the
diagnosis of EoE. In the appropriate clinical setting the finding of
any of the endoscopic features described above supports but does
not establish the diagnosis of EoE (see Table E2 and Fig E1 in this
article’s Online Repository at www.jacionline.org). Esophageal
biopsy specimens should be taken to seek histologic evidence
of EoE in patients with unexplained dysphagia, even if results
of endoscopy appear normal or identify a potential cause of dys-
phagia other than EoE.
Two to 4 mucosal biopsy specimens of the proximal and distal
esophagus should be obtained. In children and, when indicated, in
adults biopsy specimens of the gastric antrum and duodenum
should be obtained once to exclude other potential causes of
esophageal eosinophilia. There are limited data to support routine
gastric or duodenal biopsies in adults in the absence of symptoms
or endoscopic abnormalities suggesting other gastrointestinal
disorders, although it is reasonable for these biopsies to be
performed.
Radiography is not a recommended routine diagnostic test for
EoE but can be helpful in selected cases not only to characterize
anatomic abnormalities that can be difficult to define endoscop-
ically but also to provide information on the length and diameter
of complicated esophageal strictures. Findings of a narrow-
caliber esophagus (see definition in the ‘‘Disease complications’’
section) or proximal cervical esophageal stricture might be
overlooked. Communication with the radiologist regarding indi-
cations for the esophagram is important so that the entire
esophagus, including the caliber and distensibility of the esoph-
ageal lumen, will be fully assessed.
Committee future recommendations. Further studies
are needed to determine agreement among endoscopists in
identifying the endoscopic features of EoE and to define the
diagnostic utility of the individual endoscopic features of EoE.73,74
improved after treatment with topical steroids or anti–IL-5 (mepoli-
zumab).40,69 Other histologic findings, such as basal zone hyperpla-
sia, elongation of rete pegs, and dilated intercellular spaces, are also
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Update of 2007 recommendations. Eosinophils and
extracellular eosinophil granules. No prospective studies
have determined a threshold number of esophageal eosinophils that
can establish a diagnosis of EoE with high specificity and
sensitivity and consistently allow differentiation of EoE from
other causes of esophageal eosinophilia. One study that related
peak eosinophil counts in esophageal biopsy specimens from
patientswith EoE to symptom frequency or severity reported a lack
of correlation between eosinophil density and symptoms in
untreated patients with new diagnoses.70 However, another study
that correlated a composite score found some correlation between
symptom subcomponents (dysphagia and anorexia/early satiety)
and inflammation.46 Pediatric patients who had esophageal
biopsy specimens obtained between 1982 and 1999 with 15 or
more eosinophils/hpf and as few as 5 or more eosinophils/hpf
were significantly more likely to have increased eosinophil
numbers in subsequent esophageal biopsy specimens. Surface
layering and microabscesses were found only in biopsy specimens
that had 15 or more eosinophils/hpf.76 These data are supported by
a case-control study that found that the odds ratios for the findings
of basal zone hyperplasia and extracellular eosinophil granules
were 44 and greater than 100 for patients with EoE (defined as
>20 eosinophils/hpf) versus those without EoE, respectively. In
that study epithelial desquamation and microabscesses were pre-
sent only in patients with greater than 20 eosinophils/hpf.77
Some studies have shown that significant eosinophilic inflam-
mation occurs in the proximal esophagi of adults with EoE but not
GERD78; others have not confirmed this finding.6 Previous stud-
ies reported patients with EoE with increased eosinophil numbers
in the distal esophagus.79 Some have found that a significant pro-
portion of adult patients with greater than 15 eosinophils/hpf had
GERD/PPI-responsive esophageal eosinophilia.6 Currently, nei-
ther histopathology nor distribution of inflammatory changes in
esophageal biopsy specimens predicts response to PPI therapy.
However, eosinophilic microabscesses and surface layering of
eosinophils are more typical of findings associated with EoE
than GERD. In a limited number of patients, the presence of
extracellular eosinophil granules (depicted by extracellular depo-
sition of granule proteins, including eosinophil peroxidase, major
basic protein, and eosinophil-derived neurotoxin) was found to be
a useful feature for histologic distinction of EoE fromGERD.80-82
One pediatric study showed that basal cell hyperplasia and extra-
cellular eosinophil granules correlated with symptoms.77
From a technical standpoint, one study identified a benefit of
evaluating the peak number of eosinophils per hpf, as opposed to the
average number, by using the number of eosinophils, extracellular
eosinophil granules, epithelial changes, and eosinophils per hpf in
patients with EoE.51 Unfortunately, the actual size of the hpf de-
scribed inmany studies is quite variable and frequently not reported.
These limitations continue to create significant problems in compar-
ing data across institutions and between different studies.83
Associated histologic features and other cell types
observed in patients with EoE. Lamina propria fibrosis is
found in most biopsy specimens from children and adults with EoE
and has been shown to be less prevalent in biopsy specimens from
patients with GERD and healthy subjects.78,84,85 In some studies
subepithelial fibrosis was one of the histologic features thatconsistently associated with EoE, but their diagnostic specificity is
less certain.86,87 Some studies have also identified that mast cells
are increased in biopsy specimens frompatientswithEoE compared
with those from patients with GERD.24,41,81,88 IgE-bearing cells are
more common in biopsy specimens from patients with EoE com-
paredwith those from patients with GERD and are also not detected
in control specimens.24,41 The number of intraepithelial regulatoryT
cells are increased in esophageal biopsy specimens from patients
with EoE and those with GERD compared with normal mucosa
but are not significantly different when comparing EoE with
GERD.29 B-cell numbers are increased in biopsy specimens from
patients with EoE compared with those seen in control subjects as
well.41
In both murine and translational studies, the cytokine IL-5
remains a focal point. IL-5 has been identified in human biopsy
specimens and has been shown to drive eosinophil-mediated
esophageal remodeling in murine models.11,26,89 Periostin, an ex-
tracellular matrix protein associated with heart and lung repair
and remodeling, has been shown to be increased in the esophagi
of patients with EoE. The presence of periostin correlates with in-
creased eosinophil levels in patients with EoE but not in patients
whose eosinophil levels are less than the threshold criteria that
were used to define EoE.90 Confirming and expanding prior
genetic studies, expression of eotaxin-1/CCL11 and eotaxin-3/
CCL26 genes have been reported to be increased in biopsy spec-
imens from patients with EoE compared with those seen in con-
trol specimens.91,92 Fibroblast growth factor 9, IL-13, IL-15,
and TGF-b1 levels are also increased in biopsy specimens from
patients with EoE and patients with GERD compared with those
seen in normal biopsy specimens.93
Committee clinical recommendations. Histopathologic
features of esophageal mucosal biopsy specimens must be
interpreted in conjunction with the patient’s clinical information
(see Table E3 in this article’s Online Repository at www.
jacionline.org and Fig 1) Until more specific studies are per-
formed, it is important that all histologic features, including
peak eosinophil counts obtained from the most densely populated
hpf, eosinophil microabscess formation, superficial layering of
eosinophils, extracellular eosinophil granules, basal cell hyper-
plasia, dilated intercellular spaces, rete peg elongation, subepi-
thelial lamina propria fibrosis, and increases in numbers of
other cell types, such as lymphocytes, be evaluated and noted
in pathology reports. Inflammatory changes in patients with
EoE might be focal and might not be present in all biopsy spec-
imens from a single patient. Because of the nonspecific nature of
symptoms in children, assessment of gastric and duodenal mu-
cosa is recommended.
Committee future recommendations. Wide variations
in practice patterns and clinical experience have created contro-
versy and differences of opinion regarding the most optimal
method of defining eosinophil-predominant inflammation. Al-
though measurement of the absolute number of eosinophils per
hpf has allowed identification of patients with EoE, the method
remains problematic. Limitations of this method include lack of
standardization of the size of an hpf, variability in the definition of
an intraepithelial eosinophil in hematoxylin-stained tissue sec-
tions, and lack of information regarding the absolute threshold
number of eosinophils that distinguishes EoE from other causes
of esophageal eosinophilia. The diagnostic significance and
specificity of other features of eosinophil-predominant inflam-
mation, such as eosinophilic microabscess formation, superficial
erosive reflux disease underwent pH monitoring while off PPI
therapy.6 At baseline, pH testing revealed that 15 (71%) of 21 pa-
tients demonstrated pathologic acid reflux disease, whereas 6 did
FIG 1. Histology of the esophagus (mucosal biopsy specimens). A, Normal esophagus. B, EoE.
C, EoE, superficial layering of surface eosinophils (arrow). D, EoE, microabscess (arrow).
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ophil granules, are also still unknown.
Prospective studies are needed to help identify histologic
features that can differentiate EoE from other causes of esopha-
geal eosinophilia, in particular GERD. Standardization of the unit
for eosinophil enumeration (hpf vs square millimeters) might
facilitate comparison of patients between different studies. Studies
that validate associated features of inflammation (see Table E3)
might allow discrimination between EoE and GERD and might
also potentially allow differentiation of EoE phenotypes. Studies
should address practical issues, such as the optimal number of tis-
sue samples to survey, the anatomic location with the highest yield
of diagnostic mucosal biopsy specimens (proximal/middle/distal),
and the best method of quantitating eosinophils.7,94,95 Transcrip-
tome analysis of mucosal samples might potentially determine
novel pathogenetic mechanisms and allow for molecular diagnos-
tics. Expression of eotaxin-3, periostin, COX-2, IL-5, IgE, and a
large panel of EoE-specific transcripts (eg, EoE transcriptome)
should be investigated in larger studies to determine whether
they are helpful in distinguishing EoE from GERD.
Other diagnostic modalities
Update of 2007 recommendations. Studies before 2007
showed that in patients with reflux esophagitis, standard trans-
nasal and wireless capsule pH-recording systems demonstrate
variability in acid pH monitoring.66,67 One recent study detected
significantly greater symptom association with the addition of im-
pedance to pH testing compared with pH testing alone; however,
the clinical implication of this association has not been deter-
mined.96 The performance characteristics of transnasal and wire-
less pH and combination pH impedance testing in patients with
EoE are uncertain.
In a cohort study adults with esophageal eosinophilia in their
mid and proximal esophagi without endoscopic evidence ofnot. Both groups were then treated with twice-daily PPI therapy
for 2months and underwent follow-up endoscopy. Among subjects
with pathologic acid reflux, 12 (80%) had resolution of esophageal
eosinophilia, suggesting the eosinophils might have been present
in response to acid reflux. Three subjects had persistent eosino-
philia despite PPI therapy because they might have had 2 diseases
(GERD and EoE) or because they were nonadherent in taking their
PPIs. Among the 6 subjects with baseline esophageal eosinophilia
with normal pH test results, 2 (33%) demonstrated resolution of
their eosinophilia with PPI therapy, despite the lack of objective
evidence for acid reflux disease, suggesting either a lack of diag-
nostic accuracy of the pH-monitoring study to identify pathologic
acid reflux at baseline or that PPIs have an independentmechanism
for improvement of esophageal eosinophilia. Four (66%) subjects
demonstrated persistent esophageal eosinophilia, reflecting either
classic EoE or lack of subject adherence to PPI therapy.
When studied systematically in pediatric patients, neither acid
nor nonacid reflux occurs in patients with EoE in a manner that
differs from that seen in age-matched control subjects.97,98 Other
tests have assisted inunderstandingmore about the pathophysiology
of EoE but have not added effect in making the diagnosis of EoE.
One study demonstrated that patients with EoE sensed 0.1N hydro-
chloric acid earlier than comparison control groups.59 The associa-
tion of motility disturbances with EoE remain controversial, with
some studies demonstrating abnormalities, such as high amplitude
contractions, increased esophageal pressurization, and disordered
wave patterns, whereas others reveal normal motility.48,97,99-101
Prolonged esophageal manometry and pH testing in children with
EoE found that ineffective peristalsis correlated with dysphagia in
children with EoE compared with control subjects.97,100
Endoscopic ultrasonography has been shown to detect a greater
mucosal and muscular thickness in patients with EoE compared
with that seen in control subjects.97,99 Impedance planimetry (En-
doFLIP; Crospon, Inc, Carlsbad, Calif), a technology that uses a
bag filled with a conductive solution and multiple impedance
electrodes to simultaneously measure pressure and volume,
detected significant pathologic changes in esophageal wall com-
on a candidate gene approach. Now, a genome-wide analysis,
probing 550,000 common genetic variants in both a discovery and
replication cohort from multiple institutions, has identified the
38
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of esophageal dysfunction in patients with EoE.102 High-
resolution esophageal manometry with pressure topography dem-
onstrated abnormal esophageal pressurization patterns in adults
with EoE compared with that seen in patients with GERD or
healthy control subjects and might reflect reduced esophageal
compliance.101 Endoscopic confocal laser microscopy might
detect structural changes not apparent on visible light (routine)
endoscopy specific to EoE.94
Committee clinical recommendations. Esophageal pH
monitoring (and pH impedance, where available) is a useful
diagnostic test to evaluate for GERD in patients with esophageal
eosinophilia. Other testing modalities do not yet offer clear
clinical benefit in diagnostic testing.
Committee future recommendations. Well-designed
studies to investigate the role of pH and pH impedancemonitoring
in patients with GERD and EoE are needed, particularly in adults
with EoE, in whom differentiation between EoE and GERD
appears to be more problematic than in children and adolescents.
Analysis of esophageal dysfunction might provide vital informa-
tion for monitoring disease progression and therapeutic response.
Prolonged ambulatory motility monitoring, as opposed to sta-
tionary monitoring, can provide optimal insights because
abnormalities might only be intermittently present in patients
with EoE. Other testing modalities require further investigation.
GENOTYPIC FEATURES OF ESOPHAGEAL
EOSINOPHILIA
A growing body of literature supports the immunologic basis
Since the last CR, a number of pediatric, adult, and experi-and genotypic features of EoE. During the past 4 years, a number
of studies have helped shape the new conceptual definition of EoE
as an immune/antigen-mediated disease.
Update of 2007 recommendations
In the 2007 CR the basic genetic features of EoE were limited
to one study identifying the esophageal transcriptome of patients
with EoE and its distinction from the transcriptome of healthy
patients, as well patients with nonspecific chronic esophagitis
(likely reflux associated with esophageal peak eosinophils counts
<_6 eosinophils/hpf).103 Studies have validated the expression of a
unique EoE transcriptome and validated that it differentiates EoE
from GERD, with eotaxin-3 being abundantly overexpressed in
patients with EoE.91 IL-13 has been found to be specifically upre-
gulated in the esophagi of patients with EoE andmight function as
a master regulator of the EoE transcriptome.22 By using prior re-
sults that focused on the correlation of the EoE transcriptomewith
eosinophil levels, recent studies identified specific genome-wide
transcripts that correlate with IL-13 and mast cells.104,105 These
transcripts do not fully overlap with the originally described
eosinophil-associated transcriptome, suggesting the existence of
unique mechanisms involved in esophageal inflammation. Nota-
bly, abnormal gene expression is primarily reversible with disease
remission, although a set of epithelial differentiation genes has
been shown to remain abnormal andmight be important in predis-
posing to disease relapse.26,106
Genetic susceptibility loci discussed in the 2007 CR were
limited to genetic variants identified in the eotaxin-3 gene basedfirst genome-wide EoE susceptibility locus at 5q22. Two genes
located in the susceptibility haploblock include thymic stromal
lymphopoietin (TSLP), a cytokine involved in TH2 cell determi-
nation. In a broad analysis of genetic variants within 53 candidate
genes involved in allergic responses, epithelial responses, or both,
the TSLP gene was also identified as a strong susceptibility locus
for EoE, particularly when atopywas controlled, providing strong
collective evidence for the role of this pathway in EoE pathogen-
esis.39 A genetic variant in the TSLP receptor gene, located on a
pseudoautosomal region of the X-chromosome, was also linked
with EoE susceptibility in male patients, providing early insight
into a potential mechanistic contribution for this pathway into
disease pathogenesis and the known clustering of EoE in male pa-
tients.39 Additionally, a common deletion variant in the filaggrin
gene (2282del4), originally identified as a major contributing
gene to atopic dermatitis, was identified to be markedly overrep-
resented in patients with EoE compared with control subjects
without EoE.32 Interestingly, the filaggrin association appeared
to be independent of the presence of atopic dermatitis in patients
with EoE. Finally, a pilot study suggested that particular genetic
variants in the TGFB gene might correlate with the presence of
esophageal TGF-b levels and response to therapy.69
Committee clinical recommendations. The clinical use
of specific genotypes to predict EoE diagnosis, prognosis, or both
is not yet ready for clinical application. However, esophageal gene
expression is likely to emerge as a key molecular analysis that
helps differentiate EoE from other states, including GERD, to
determine glucocorticoid-responding and nonresponding patients
and to distinguish treated EoE (particularly useful when patients
are medically treated with topical steroids before a PPI-confirmed
diagnosis of EoE has been made). Clearly, genetic factors
contribute to EoE susceptibility, and a combination of common
variants likely play amajor role in specifying the particular patient
phenotype.
Committee future recommendations. The committee
values the need for larger and well-characterized cohorts for
genome-wide and candidate gene analysis, particularly examin-
ing more rare genetics variants than included in traditional
genome-wide association studies. Identifying specific genotypes
of patients with esophageal eosinophilia who are resistant to PPI
therapy (classic EoE) and those with PPI-responsive esophageal
eosinophilia is warranted. Further analysis of the genetic variants
that contribute to atopic features of EoE (including the apparent
nonatopic EoE group) and determining the relationship of these
variants to other atopy and GERD susceptibility loci are areas of
research need. Multisite studies aimed at validating the value of
the EoE transcriptome for molecular diagnosis are also needed. In
addition, adequately powered studies using well-defined patient
populations designed to distinguish EoE from other esophageal
eosinophilic conditions are needed.
GENERAL ALLERGIC EVALUATION
Update of 2007 recommendationsmental model EoE studies have extended the concept that EoE is
an antigen-driven allergic condition, thus supporting the concep-
tual definition of EoE described above. EoE is often one of
multiple concurrent allergic diatheses, with 28% to 86% of adults
and 42% to 93% of pediatric patients having another allergic
disease.53,107-112 Several studies have reported that 50% to 60%of
53,107,113
patients with EoE, with 40% to 50% having increased numbers
of circulating eosinophils (>300-350 per mm3).3,77,119 Peripheral
eosinophilia decreases after successful esophageal topical
sought to address potential peripheral EoE biomarkers and
diatric and 2 adult studies support previous findings suggesting
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2007, the rates of allergic diatheses have been better described,
especially among adults with EoE. The majority of patients
with EoE have sensitization to food allergens, aeroallergens, or
both based on positive skin prick test (SPT) responses or serum
specific IgE test results. There is a subset of patients with EoE
who are not sensitized to food allergens, aeroallergens, or both,
as determined by using specific IgE testing. Current studies dem-
onstrate local IgE production and increase FceRI-positive cell
numbers in patients with EoE.41,42
IgE-mediated food allergy. The testing method and def-
initions of food allergy vary among studies, but estimates of IgE-
mediated immediate food hypersensitivity in patients with EoE
range from 15% to 43%.53,107 Higher rates of food-induced ana-
phylaxis can occur in patients with EoE based on current data us-
ing established guidelines for the diagnosis of food-induced
anaphylaxis.114 The presence of documented IgE-mediated food
allergy can be a predictive factor for EoE in adult and pediatric
patients.3
Airway and cutaneous allergy: Allergic rhinitis,
asthma, and eczema. Rates of allergic rhinitis, asthma, and
eczema in children and adults with EoE range from 40% to 75%,
14% to 70%, and 4% to 60%, respectively.32,77,107,109,111,115 Six
articles document seasonality associated with EoE diagnosis, sug-
gesting a potential inciting role for aeroallergens in patients with
EoE.3,53,108,110,116 In experimental EoE models perennial house-
hold allergens (dust mite and cockroach) andmolds induce esoph-
ageal eosinophilia.117,118 Additional accumulating evidence
supports EoE pathogenesis as a TH2-associated disease with in-
creased levels of esophageal mast cells, IL-13, IL-5, TGF-b1,
IgE, and FceRI-positive cells.22,41,42,84,89,105 Esophageal remod-
eling appears to play a role in esophageal dysfunction in a process
pathogenically similar to asthma.27,84,85
Committee clinical recommendations
A thorough evaluation by an allergist or immunologist is
recommended because of the high rates of concurrent asthma,
allergic rhinitis, eczema, and food allergy/anaphylaxis; the
potential seasonality of EoE diagnoses; and the complex interplay
among multiple allergic diatheses. Additional testing for asthma
and allergies is recommended to improve the diagnosis and
control of concurrent atopic diseases.
Committee future recommendations
Future publications should clearly document and use standard
definitions of allergic rhinitis, asthma (including asthma severity
and level of control), and food allergy (rather than sensitization)
when assessing and documenting concurrent allergic diseases in
patients with EoE. Studies that assess the clinical effect of a
‘‘nonallergic’’ EoE phenotype on disease progression, therapeutic
response, or both would be of interest.
LABORATORY EVALUATION
Peripheral eosinophil counts and eosinophil
granule proteins
Update of 2007 recommendations. Four studies have
documented peripheral eosinophilia in adult and pediatriccorticosteroid therapy and can correlate with tissue eosinophil
numbers (r5 0.68).120 One study suggests that esophageal eosin-
ophils in patients with EoE express HLA-DR, invoking the capac-
ity of eosinophils to act as antigen-presenting cells.121 Peripheral
eosinophil cationic protein levels did not correlate with tissue
eosinophil numbers, although there were statistically nonsignifi-
cant eosinophilic cationic protein decreases after therapy.120
Cytokines and PBMCs
Update of 2007 recommendations. Several studies haveresponse to treatment. Multiplex plasma assays showed that
patients with food allergy and EoE had increased levels and
spontaneous dendritic cell release of IL-5 and IL-13.45 Plasma ba-
sic fibroblast growth factor and serum IL-15 levels have recently
been reported to be increased in patients with EoE compared with
those seen in control subjects, and IL-15 levels might decrease af-
ter medical treatment.104,122 Adults with EoE had significantly
decreased levels of the serum chemokine thymus and
activation-regulated chemokine after treatment with oral budeso-
nide, but thymus and activation-regulated chemokine levels did
not correlate with tissue eosinophil numbers. An intriguing study
in adults with allergic eosinophilic gastroenteritis noted a pheno-
typic distinction between TH2 cells, with increased numbers of
food allergen–specific IL-51 TH2 cells in eosinophilic gastroen-
teritis but IL-52 TH2 cells in IgE-mediated peanut allergy; this in-
teresting observation warrants evaluation in patients with EoE.123
Emerging studies have identified candidate surrogate disease
markers in patients with EoE. Areas of uncertainty include the
degree of correlation with EoE disease activity and the ability of
these markers to distinguish atopic persons with or without EoE.
Committee clinical recommendations. There is cur-
rently insufficient information to support the clinical utility of any
single peripheral marker to function as a surrogate disease
indicator of histologic inflammation in patients with EoE.
Although peripheral eosinophil counts can correlate with tissue
eosinophilia in some patients with EoE, if obtained, changes in
peripheral eosinophilia should be interpreted with consideration
for the patient’s age, adherence to aeroallergen avoidance, pollen
season, and control of comorbid allergic disease.
Total IgE
Update of 2007 recommendations. One additional pe-that total IgE levels are increased (>114 kU/L) in 50% to 60% of
patients with EoE.109,111 Higher total IgE levels are reported in
allergen-sensitized versus nonsensitized patients with EoE. Total
IgE levels were not predictive of the therapeutic response in one
study (budesonide) and did not decrease by 15 days of treatment.
Committee clinical recommendations. There are cur-
rently inadequate data to support the utility of measuring the total
IgE level as a surrogate disease indicator of histologic inflam-
mation in patients with EoE.
Committee future recommendations. Future candidate
surrogate disease marker studies in patients with EoE should
include large, multicenter, longitudinal studies of adult and
pediatric patients with EoE compared with healthy, GERD,
and atopic control populations. Reasonable peripheral marker
candidates include IL-5, IL-13, IL-15, eotaxin-3, basic fibroblast
Food-specific IgE
Update of 2007 recommendations. Four articles docu-
mented serum specific IgE in patients with EoE.77,109,111,126 None
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Aeroallergen-specific IgE
Update of 2007 recommendations. The presence of
allergic rhinitis, sensitization to aeroallergens, or both ranges
from 24% to 78% in adult patients and 42% to 93% in children
with EoE.53,77,107,108,110,111,114,118,124
Several studies (2 pediatric and 1 adult) clearly documented the
presence of aeroallergen-specific serum IgE in patients with
EoE.77,109,111 Overall, 44% to 86% of patients have serum IgE to
outdoor, indoor, or both inhalant aeroallergens. Thirty-two per-
cent of pediatric patients had serum IgE to a cluster of aeroaller-
gens that included pollens and grains, soy, and nuts/peanuts; 86%
of adults have polysensitization to aeroallergens; and 61% (11/18)
of patients had birch-associated oral allergy syndrome.109,111
Current studies document rates of 71% to 93% for SPT
positivity to aeroallergens in pediatric and adult patients with
EoE.3,111,114,118,119,124,125 Publications since 2007 have docu-
mented sensitization rates through SPTs to outdoor aeroallergens,
including grass, weeds, trees, and molds (64% to 93%), and in-
door aeroallergens, including dog, cat, cockroach, and dust mites
(16% to 69%).77,107,108,111,116,118 Even in the pediatric popula-
tion, inhalant sensitization was as high as food sensitization,
and it is common for adult and pediatric patients to have polysen-
sitization to aeroallergens.
Retrospective analyses show decreased EoE diagnosis in
the winter and increased diagnosis in the spring, summer, and
fall in a total of 583 pediatric and adult patients with
EoE.3,53,107,108,110,116 Tree and grass pollen levels can directly
correlate with the numbers of patients given a diagnosis of EoE.
Sensitization to pollens that cross-react with plant-derived food
allergens might provide a link between pollen sensitization and
subsequent food ingestion in triggering EoE, although studies to
address this possibility are currently lacking.
Committee clinical recommendations. Because numer-
ous studies document aeroallergen sensitization and seasonal
variability in patients with newly diagnosed EoE, a complete
evaluation of patients with EoE for aeroallergen sensitization is
frequently warranted in both adult and pediatric patients because
this might alter clinical management.
Aeroallergens might have a complementary role in EoE
pathogenesis, and appropriate avoidance measures should be
recommended. Treating physicians might want to consider a
patient’s aeroallergen sensitization profile and seasonality when
assessing esophageal biopsy results in patients with EoE.
Committee future recommendations. Seasonality,
whether driven by aeroallergens or the consumption of seasonal
foods, requires further investigation. Studies that document clear
EoE instigation, propagation, and/or exacerbation by aeroallergens
in human subjects are warranted but likely difficult to perform
because of the need for biopsy evaluation. Surrogate markers for
EoE might help in this regard. Studies that document the effects of
aeroallergen-specific immunotherapy in patients with EoE would
be of interest. Prospective studies documenting aeroallergen
sensitization in larger populations of patients with EoE and
examining the potential correlation between seasonal variability
in symptoms and relevant pollen sensitization are needed.of these studies documented the clinical significance of serum IgE
sensitization to EoE diagnosis or management. Sensitization to
foods is common in children with EoE, and one study suggested
that food-specific IgE testing might be more sensitive than SPTs,
but the significance of these positive test results remain unclear.
Current studies of adults with EoE indicate a higher rate of
positive test results to foods than was appreciated before the 2007
CR. Among adult patients, 50% had positive results to at least
1 food, the most common being peanut (38%), egg (27%), and soy
(23%).125,127 Additional publications concerning children continue
to show higher rates of positive test results to foods than generally
reported from the adult studies.25,110,111,124 Although studies sup-
port a high rate of sensitization to foods in patients with EoE and
a subset of patients with EoE might have acute allergic reactions
to foods, warranting evaluation for IgE-mediated food allergies,
there are limited data addressing the diagnostic value of SPTs for
identifying foods thatmight directly contribute toEoE. Inone study
more than 20 subjectswere evaluated for the relationship of SPTre-
sults tomilk, egg, soy, wheat, corn, and beef to outcomes of dietary
elimination in patientswithEoE.25 Positive predictive value ranged
from 57% to 96%, negative predictive value ranged from 58% to
75%, specificity ranged from 14% to 65%, and sensitivity ranged
from90% to98%.Skin testswere slightlymore sensitive thanpatch
tests and generally less specific. Only one study documented pre-
dictive values for SPTs, and no studies documented predictive
values for serum IgE-based dietary elimination.25 Local production
of IgE in patientswithEoEmight explain a potential disconnect be-
tween positive test results and actual EoE food triggers.41
Several additional studies with regard to food atopy patch tests
(APTs) have been reported.16,25,110,111,114,126,127 Positive patch
test rates range from 30% to 95% in children and adults with neg-
ative predictive values of greater than 90% (except milk, with a
negative predictive value of 50%) and variable positive predictive
values in children.127 Using SPT- and APT-based elimination
diets, milk and egg were the most common EoE triggers in chil-
dren. Food patch testing remains to be standardized and validated
in children and adults. Evidence that APTs induce a local immune
response reflecting the immunopathology seen in patients with
EoE also remains to be demonstrated.
Committee clinical recommendations. Because of the
high rates of food allergies and anaphylaxis in patients with EoE,
serum IgE and skin prick testing for immediate-type food allergy
is warranted to identify comorbid food-induced allergic disease in
patients with EoE.
The clinical utility of IgE testing for dietary intervention in
patients with EoE remains largely unknown. Medically super-
vised food reintroduction might be necessary for patients with
previous allergic reactions to a food or IgE-mediated sensitivity
documented by SPT responses, serum food-specific IgE levels, or
both because loss of tolerance during food avoidance might result
in significant reactions on reintroduction of the food.128-130 Pa-
tients with EoE who are found to have positive skin test results
to foods should be appropriately evaluated for immediate hyper-
sensitivity reactions and prescribed epinephrine, if indicated.
Food triggers in patients with EoE can currently only be identified
by documenting disease remission after specific food antigen
elimination followed by EoE recrudescence on specific food
reintroduction. As such, although SPTs, serum IgE tests, and food
patch tests can be used to help identify foods that are associated
with EoE, these tests alone are not sufficient tomake the diagnosis
131
needed not only to clarify PPI-responsive esophageal eosinophilia
but also the endoscopic and histologic features that might
distinguish GERD from EoE. Emerging data suggest a potential
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Committee future recommendations. The clinical util-
ity of serum food-specific IgE levels and SPT responses for
generating successful food antigen elimination diets in patients
with EoE and the use of commercial food extracts versus fresh
foods for SPTs and APTs in patients with EoE require further
investigation. Multicenter studies that standardize and validate
food APTs in patients with EoE are needed. Future studies should
clearly document clinical and histologic benefit from food APTs,
SPTs, and/or serum IgE–directed dietary interventions. Studies
that evaluate food antigen–specific PBMCs as an invitro diagnostic
test for food allergy in patients with EoE would be of interest. Fur-
ther studies that evaluate the potential increased efficiency of com-
bined testing methods (serum and/or SPTand/or APT) in directing
successful dietary elimination in patients with EoE are needed.
MEDICAL AND DIETARY THERAPY
PPI therapy
Update of 2007 recommendations. As previously re-ported in the 2007 CR, acid suppression continues to be an
effective tool in fulfilling the diagnostic guidelines for EoE. PPI
therapy is useful in treating patients with esophageal eosinophilia
secondary to GERD.6,132,133 Patients with isolated esophageal
eosinophilia who are treated with PPIs and have a significant
improvement of their symptoms and esophageal eosinophilia
either have GERD or a yet undefined PPI-responsive esophageal
eosinophilia3,134; the lack of a clinicopathologic response to PPI
treatment in patients adherent to the treatment regimen with
compatible symptoms of EoE and isolated esophageal eosinophilia
is consistent with the diagnosis of EoE (see the ‘‘Diagnostic guide-
lines’’ section).110 However, apart from PPI-responsive esophageal
eosinophilia, PPIs might be useful as a cotherapy in patients with
diagnosed EoE because they might alleviate symptoms related to
secondary GERD, which might be present with EoE.59 PPI therapy
alone is not effective as a primary treatment for patients with EoE.
Committee clinical recommendations. In many patients
PPIs are useful to help eliminate GERD as a cause of esophageal
eosinophilia. The recommended PPI dose that should be used to
eliminate PPI-responsive esophageal eosinophilia is 20-40 mg,
once or twice daily for 8 to 12 weeks in adults (depends on patient
and chosen PPI), and 1 mg/kg per dose, twice daily for 8 to 12
weeks in children (for maximal dosing use adult recommenda-
tions). PPIs are useful in treating patients with EoE in whom
GERD is a comorbid disease. Finally, although the mechanism of
PPIs is thought to primarily involve acid blockade, PPIs might
also affect esophageal eosinophilia by means of other mecha-
nisms and thus be helpful in a subset of patients described as
having PPI-responsive esophageal eosinophilia.
Committee future recommendations. Patients with EoE
might have an enhanced sensitivity to acid, even in the absence of
pathologic reflux defined by conventional pH criteria. As a result,
the presence of both GERD and EoE in a patient might not
represent simple coexistence but instead a synergistic mecha-
nism. Therefore the committee recommends additional studies
clarifying the relationship among esophageal acid exposure and
its capacity to increase eotaxin-3 production, esophageal eosin-
ophilia, and clinical symptoms. In addition, future studies arerole for endoscopic ultrasound, deep tissue biopsies to examine
for lamina propria fibrosis, identification of activated mast cells,
and evaluation of the esophageal transcriptome.
Dietary therapy
Update of 2007 recommendations. Dietary therapy
continues to be effective in children given a diagnosis of EoE.
The literature continues to demonstrate that the use of dietary
therapy leads to near-complete resolution of both clinical and
histologic abnormalities.110,135 One study suggested that dietary
restriction might reverse esophageal fibrosis.136 Three dietary
regimens have been shown to be effective: (1) the strict use of
an amino acid–based formula, (2) dietary restriction based on
multimodality allergy testing, and (3) dietary restriction based
on eliminating the most likely food antigens. Similar results (clin-
ical and histologic response) have been documented when using
either method of dietary restriction; however, when compared
with the administration of a strict elemental formula in allergic
patients, elemental formula continues to be the most effective
dietary therapy.137 Available data suggest that tolerance to foods
associated with EoE is unlikely to develop spontaneously, even
after prolonged elimination.110 Furthermore, methods to induce
tolerance in patients with EoE have not been evaluated.
Committee clinical recommendations. Dietary therapy
should be considered in all children given a diagnosis of EoE.
Preliminary observations suggest that dietary restriction should also
be considered formotivated adult patientswithEoE.Whendeciding
on the use of a specific dietary therapy, the patient’s lifestyle, adher-
ence to therapy, and family resourcesneed tobeconsidered.Consul-
tation with a registered dietitian is strongly encouraged to ensure
that proper calories, vitamins, and micronutrients are maintained.
The committee suggests that foods proved to cause EoE continue
to be restricted from the diet, whereas those foods not definitively
proved to be antigenic can be reintroduced systematically, with
careful observation for recurrence of EoE. Restriction of foods
proved to trigger EoE might need to be continued indefinitely.
Committee future recommendations. The use of die-
tary therapy in adults requires further study. In addition, further
research needs to be performed with regard to the effect of dietary
restriction on esophageal fibrosis, quality-of-life issues, adher-
ence to therapy, development of food antigen tolerance, nutri-
tional effects and possible consequences of prolonged dietary
restriction, and best ways to identify foods (eg, skin prick, serum
IgE, and patch testing) that cause EoE.
Corticosteroid therapy
Update of 2007 recommendations. Corticosteroids con-
tinue to be an effective therapy in children and adults given
diagnoses of EoE.138 Steroids improve the clinicopathologic
features of EoE in most patients; however, when discontinued,
the disease almost always recurs.139 Systemic corticosteroids
can be used for emergency cases, such as severe dysphagia, hos-
pitalization, and weight loss.140 Because of the potential for sig-
nificant toxicity, the long-term use of systemic steroids is not
recommended. Topical corticosteroids continue to be effective
in inducing EoE remission, although steroid resistance (as dem-
onstrated by the lack of histologic responsiveness and the failure
to modify local esophageal gene expression) has been
reported.33 Additional studies have documented their short-term
safety, except for local fungal infections. Before 2007, flutica-
sone was primarily used. Since then, oral viscous budesonide
112,120
DISEASE COMPLICATIONS
Update of 2007 recommendations
In the 2007 CR, little information was available regarding the
TABLE III. Recommended doses of corticosteroids for EoE
Topical swallowed corticosteroids
Initial doses (see references for preparation and administration
information)
Fluticasone (puffed and swallowed through a metered-dose inhaler)
Adults: 440-880 mg twice daily
Children: 88-440 mg twice to 4 times daily (to a maximal adult dose)
Budesonide (as a viscous suspension)
Children (<10 y): 1 mg daily
Older children and adults: 2 mg daily
Systemic corticosteroids
For severe cases (eg, small-caliber esophagus, weight loss, and
hospitalization)
Prednisone: 1-2 mg/kg
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some evidence that budesonide can reverse esophageal
fibrosis.69
Committee clinical recommendations. Topical cortico-
steroid therapy should be considered in all children and adults
given a diagnosis of EoE for both initial and maintenance therapy
(Table III). The type and duration of steroid therapy depends on
the disease severity, the patient’s lifestyle, the ability of the
patient to continue the medication, and family resources. Doses
of various steroid preparations are listed in Table III. Clinical
experience and concern for ongoing symptoms, esophageal in-
flammation, and complications of untreated disease has led to
the recommendation that after induction of clinicopathologic
remission, topical corticosteroid therapy might need to be main-
tained; however, long-term therapy must be individualized for
each patient. When topical steroids are used chronically, in addi-
tion to observing for side effects, growth should be carefully mon-
itored in children.
Committee future recommendations. Further studies
are needed to clarify the specifics of topical steroid therapy. Most
importantly, investigation needs to be performed regarding the
most effective topical steroid dose required for initial disease
treatment and maintenance therapy for both children and adults.
In addition, further research needs to be performed with regard to
steroid resistance, the effect of corticosteroids on esophageal
fibrosis, the need to treat to histologic normalcy, quality-of-life
issues, growth, consequences of prolonged use (eg, adrenal
suppression), and steroid effects on bone density.
Cromolyn sodium, leukotriene receptor
antagonists, biologics, and other therapies
Update of 2007 recommendations. No additional infor-mationhas been reportedwith regard to the use of cromolyn sodium
or leukotriene receptor antagonists in patients with EoE. Cromolyn
sodium has no apparent therapeutic benefit for patients with EoE.
Leukotriene receptor antagonists might induce symptomatic relief
when given at high dosages; its use has no demonstrable effect on
esophageal eosinophilia.141 In a single study anti–TNF-a had no
benefit in patients with EoE.142 A few studies in a small number
of patients have been published using anti–IL-5. The studies dem-
onstrated a significant decrease in esophageal eosinophil numbers
and improvement in a few parameters of esophageal remodeling;
however, the clinical response was variable.40,143
Committee clinical recommendations. Treatment of
EoE with cromolyn sodium, leukotriene receptor antagonists, and
immunosuppressive agents (azathioprine or 6-mercaptopurine) for
the treatment of EoE is not recommended. The lack of combined
clinical and histologic benefit and potential side effects currently
outweighanypotential benefit.Biologicagentsawait further clinical
studies and are not recommended for routine use at the present
time.144 Several additional studies on anti–IL-5 therapy are pending.
Committee future recommendations. Other potential
agents for the treatment of EoE should be investigated. Potential
future treatments include immunosuppressive agents and the use
of mAbs, such as anti–IL-5, anti–IL-13, and anti-eotaxin. In
addition, the study of serum biochemical markers might aid in the
development of potential future therapies.definitions, prevalence, and management of EoE complications,
including food impaction, esophageal stricture, narrow-caliber
esophagus, and esophageal perforation. The understanding of
EoE complications is hindered by the lack of uniform definitions
for these well-recognized problems. The wide ranges of reported
prevalence figures reflect not only variability of definitions of
these complications but also differences in patient selection,
period of follow-up, and treatment patterns.
Food impaction was defined as an event occurring after food
ingestion, where foodmatter is retained in the esophagus, requiring
either an emergency physician visit or endoscopic intervention.
Self-limited food retention or transient dysphagia after eating not
requiring intervention would not qualify as food impaction in this
definition. Although such a definition overlooks clinically signif-
icant but self-resolving impaction, the committee considered it
preferable to a definition that arbitrarily designates duration or
severity of symptoms or other less quantifiable outcome. By using
the definition of food retention requiring endoscopic extraction, the
prevalence of food impaction among larger adult series of patients
with EoE (>50 subjects) ranged from 30% to 55%.3,53,145,146 In ad-
dition to these cohorts, investigators have assessed patients present-
ing with esophageal food impaction to define the proportion of
impactions occurring secondary to EoE. Adult series have reported
that 11% to 55% of food impactions demonstrated EoE.61,147,148
Stricture definition is problematic, given that esophageal rings
are a common manifestation of the disease state in adults and
because rings imply some degree of esophageal stricture. Similar
to Schatzki rings, the rings in patients with EoE have an axial
length of less than a fewmillimeters. Stricturesmight be arbitrarily
differentiated by a length of greater than 1 cm. The committee
considered rings and strictures as distinct entities, as reported in
the literature. With respect to narrow-caliber esophagus, this is
differentiated from a stricture by the generalized involvement of
the majority of the esophagus. Although a radiographic definition
might be preferable to endoscopic assessment, most reports of this
outcome used a subjective endoscopic impression to classify
patients. Stricture prevalence in larger adult series ranged from
11% to 31%.3,53,71,145,149-151 Narrow-caliber esophagus has a re-
ported prevalence of approximately 10% in larger series.3,115,145
The definition of esophageal injury patterns should be exam-
ined on the basis of the following suggested classification scheme.
A full perforation or Boerhaave syndrome is characterized by a
full-thickness tear with esophageal or gastric contents in the chest
cavity that requires surgical treatment, usually with thoracotomy,
drainage, repair, and possible resection. A partial rupture is
defined by limited air or contrast extravasation into the medias-
Committee future recommendations
Standardized definitions for EoE complications of esophageal
stricture, narrow-caliber esophagus, food impaction, and perfo-
A number of reports have described the use of esophageal
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Esophageal intramural tears are identified endoscopically as
deep lacerations extending into the esophageal submucosa or
radiographically by contrast extending outside the esophageal
lumen but contained within the esophageal wall. Circumferential
intramural dissection is defined by circular detachment of the
esophageal mucosa and not associated with leakage of esophageal
contents into the mediastinum or thoracic cavities.
There have been 19 patients with EoE reported with sponta-
neous or non–dilation-related perforation, and of the 14 sponta-
neous perforations, there were 2 full perforations and 12 partial
tears.146,152-159 Five postendoscopy perforations without preced-
ing esophageal dilation were partial tears.160-162 Of the 19 perfo-
rations reported, 7 patients required surgical intervention (ie, 4
primary repairs and 3 esophageal resections). None of the re-
ported perforations have been fatal. Three cases of circumferen-
tial intramural dissection and numerous cases of spontaneous
and endoscopy-associated esophageal intramural tears have
been reported.146,158,159
A number of medical and dietary approaches have been studied
for EoE. Limited data are available on the effect of these therapies
on complications of EoE. The majority of data exist regarding the
effect of topical steroids on the incidence of food impaction in
adults with EoE. In a retrospective study of 21 adults treated with
fluticasone for 6 weeks, the prevalence of food impaction
decreased from 71% to 0 %.163 A prospective study reported
food impaction in 83% before therapy and 0% after 12 weeks
of fluticasone.151 The 15-day treatment period in a randomized
controlled trial of budesonide allowed for detection of a signifi-
cant improvement in dysphagia but was too short a treatment pe-
riod to determine an effect on food impaction.133 A randomized
controlled trial of fluticasone for 6 weeks reported food impaction
in 81% of patients receiving placebo and 76% of those receiving
fluticasone. After therapy for 6 weeks, no food impactions were
observed in either group. A retrospective study of 32 adults
with EoE who were contacted a mean of 3 years after therapy
with 6 weeks of fluticasone observed recurrent dysphagia in
91% and food impaction in 28%.139 Available data on systemic
steroids and elimination and elemental diets have been largely
confined to pediatric studies in which the baseline prevalence of
food impaction was either low (<20%) or not reported.
Although concerns of additional long-term complications of
esophageal cancer and progression of EoE to a generalized
eosinophilic disorder exist, there has been no evidence of such
complications to date. Six case reports have described patients
with coexistent Barrett esophagus and possible EoE, one of whom
had low-grade dysplasia.164-167 The finding of Barrett esophagus
in patients with EoE does not imply causality given the high prev-
alence of GERD and Barrett esophagus in the general population.
Committee clinical recommendations
The diagnosis of EoE should be considered in patientspresenting with food impaction, unexplained esophageal stric-
tures, narrow-caliber esophagus, and spontaneous or endoscopic
esophageal perforation. Clinicians should be aware of the risk of
esophageal perforation in the setting of food impaction and with
diagnostic endoscopy in patients with EoE.ration are needed. Symptom assessment of self-limited food
impaction is of clinical importance but difficult to define for
research studies. Future studies on EoE should incorporate
standardized definitions of complications of EoE to allow more
accurate comparisons of outcomes across studies. Greater atten-
tion is needed to assess the effect of EoE and EoE therapy on
patient-reported quality of life. Natural history studies are needed
to define the long-term risks of EoE in terms of progression of
disease and consequences of esophageal inflammation.
ESOPHAGEAL DILATION
Update of 2007 recommendationsdilation to address stricture formation in patients with EoE. Initial
reports of complications related to esophageal dilation in patients
with EoE included not only chest pain but also perforation. Of the
84 adult patients reported before 2008 who underwent dilation,
5% experienced an esophageal perforation and 7% were hospi-
talized for chest pain, rates substantially higher than those quoted
for esophageal dilation for other benign strictures.168 Such find-
ings led to the 2007 recommendation that medical or dietary ther-
apy for EoE be attempted before the performance of esophageal
dilation.1
Three recent retrospective studies from adult centers reported
complication rates, secondary to perforation or resulting pain,
requiring hospitalization rates that were considerably lower than
those of initial reports.71,169,170 Only 3 perforations were reported
among 404 patients undergoing 839 esophageal dilations. Incor-
porating this recent information for esophageal dilation of pa-
tients with EoE, the perforation rate is 0.8%, and the chest pain
rate is 5%. Furthermore, perforations that did occur were partial
ruptures and mainly determined by means of extravasation of
air and not contrast or gastric contents. None of the reported per-
forations required surgical intervention. In the largest study post-
procedural pain was reported in 5% on chart review but in 74% on
a patient-reported questionnaire. Major bleeding defined by need
for endoscopic hemostasis or blood product transfusion was re-
ported in only 1 patient.
In spite of the greater safety margin reported in these recent
studies of esophageal dilation, the optimal role of dilation as
therapy of EoE is still controversial and should be individual-
ized until more data are available.168 Dilation can provide im-
mediate and long-lasting relief of dysphagia in patients with
high-grade esophageal strictures. In adults EoE occurs primarily
in otherwise healthy young to middle-aged patients, who, if
given the option, might prefer periodic dilation to regular use
of a medication or an elimination diet. A very high degree of
patient acceptance for primary therapy with esophageal dilation
was reported in a postdilation survey.71 Furthermore, although
symptom response after medical and dietary therapy is high,
the reversibility of esophageal strictures is poorly studied. On
the other hand, the greater safety reported in the recent larger
series might reflect the adoption of a more careful and conser-
vative approach by experienced gastroenterologists aware of
the potential hazards of dilation in patients with EoE. Finally,
monotherapy with dilation does not address the underlying in-
flammatory process.71
Committee clinical recommendations
Esophageal dilation with or without concomitant medical or
dietary therapy can provide relief of dysphagia in selected
Although such tears have been described in patients with EoE,
there is no information that suggests that these tears represent
anything more than a successful dilation.
published in 2007, there has been a significant increase in clinical
TABLE IV. Major unresolved issues affecting the diagnosis and treatment of EoE
1. Optimization of methodologies for histologic analysis of mucosal samples
A. Number of biopsy specimens
B. Proximal versus distal biopsy specimens
C. Number of hpfs that need to be examined
D. Effect of associated histologic features on diagnostic sensitivity
E. Mean versus peak number of eosinophils
F. Size of hpf used to quantitate eosinophils
G. Use of completely filled versus partially filled hpfs
H. Reporting eosinophil density as number per hpf versus number per unit area (mm2)
I. Eosinophil degranulation and optimal markers (MBP, EPO, and EDN)
2. Exclusion of esophageal acid/nonacid disease (PPI therapy and diagnostic testing)
3. Lack of consensus on criteria to diagnose eosinophilic disease in the remainder of the gastrointestinal tract
4. Allergy testing in adults and children in guiding dietary exclusions
5. Optimal end points of treatment (eg, symptom relief and histologic normalcy)
6. Frequency of endoscopy in follow-up (Is it needed in asymptomatic patients?)
7. Maintenance treatment (dose and duration)
8. Validated measurements of symptoms, endoscopic findings, histology, and quality of life
EDN, Eosinophil-derived neurotoxin; EPO, eosinophil peroxidase; MBP, major basic protein.
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stenosis, a trial of medical or dietary therapy before perfor-
mance of esophageal dilation is reasonable. For high-grade
strictures, dilation before initiation of medical therapy has been
well tolerated and effective. The risk of chest pain after dilation
is significant and should be discussed with patients. The use of
esophageal dilation as primary therapy without concomitant
medical or dietary therapy does not address the underlying
inflammatory process and has been inadequately studied. On the
other hand, the degree to which esophageal strictures will
reverse with medical or dietary therapy alone is uncertain.
Although the risk of perforation is low, a more conservative and
careful approach in the esophageal dilation technique is advised
for patients with EoE compared with those with other benign
entities, such as Schatzki ring or peptic stricture. Techniques
described for esophageal dilation in patients with EoE include the
use of both through-the-scope and bougie dilators. Bougies might
be preferred because the esophageal lumen can be narrowed in
multiple sites and sometimes diffusely. Advocates of through-the-
scope balloons point to 2 theoretical advantages: they apply
exclusively radial force during dilation and afford the ability to
immediately assess esophageal injury. The practice of gradual
esophageal dilation with a target goal of 15 to 18 mm and limiting
the progression of dilation diameter per session to 3 mm or less
after resistance is encountered is reasonable but has not been
specifically addressed in patients with EoE. Furthermore, this
dilation approach has not beenvalidated and applies to bougie and
not through-the-scope balloon dilation. Multiple dilation sessions
are often required for high-grade esophageal stenosis in patients
with EoE. Monitoring progressive dilations during a single
session with repeat endoscopy to examine for mucosal tears is
controversial. This is more readily achieved with through-the-
scope balloons and more cumbersome with bougie dilation.
Complications of dilation can be associated with younger age
and more dilations, narrowing in the upper third of the esophagus,
and inability to traverse the narrowing with the scope before
dilation.170,171 These predictors of risk were largely based on in-
clusion of esophageal intramural tears as a complication.Committee future recommendations
Prospective studies are needed to define the role of esophageal
dilation in the management of EoE. Such studies will help define
technical factors to optimize response and minimize risk of
dilation. Studies are also needed to assess the degree of stricture
response to medical and dietary therapy of EoE that would
obviate the need for esophageal dilation.
CONCLUSIONS AND FUTURE GOALS
Since the initial set of recommendations and guidelinesexperience and the number of publications on the subject of EoE.
However, despite the growing interest and ever-increasing body
of literature, a great deal remains unknown (Table IV). Because of
the confusion between esophageal eosinophilia and EoE, we pro-
vided both a conceptual definition of and diagnostic guidelines for
EoE to assist clinicians in identifying the differences between his-
tologic findings and the disease process. In addition, we anticipate
that this definition and guidelinewill help to shape future research
focusing on critical clinical and pathogenetic questions. As clin-
ical experience broadens and research discovers more intriguing
features of this disease, modifications of the presented definition
and guideline are inevitable. Future challenges include develop-
ing appropriate translational studies that will allow definition of
EoE phenotypic subsets. Of importance is the need to differentiate
EoE from GERD, which has caused much controversy. Other im-
portant questions that mandate future research surround allergic
testing, treatment approaches, the genetic basis of the disease,
and diagnostic criteria, including molecular markers, the use of
dilation, and the management of the complications of EoE.
The joint effort of pediatric and adult clinical and basic
scientists in a variety of subspecialties has been paramount in
the rapid understanding of this disease process. It is critical that
leaders from all of the above specialties continue towork together
and undertake studies on natural history, pathophysiology, bio-
markers, diagnosis, and therapeutic approaches not only to
increase the scientific and clinical knowledge of EoE but also to
improve the lives of children and adults affected by the disease.
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What do we know?
d EoE is a clinicopathologic disease isolated to the esophagus.
d EoE represents a chronic, immune/antigen-mediated,
esophageal disease characterized clinically by symptoms
related to esophageal dysfunction and histologically by
eosinophil-predominant inflammation.
d With few exceptions, 15 eosinophils/hpf (peak value) is
considered a minimum threshold for a diagnosis of EoE.
d Endoscopy with biopsy is currently the only reliable diag-
nostic test for EoE.
d An allergy evaluation is warranted in patients given a di-
agnosis of EoE.
d The disease should remit with treatments of dietary exclu-
sion, topical corticosteroids, or both.
What is still unknown?
d Pathophysiology of PPI-responsive esophageal eosinophilia
d Pathognomonic features that define EoE
d Optimal histologic descriptive elements that characterize
EoE
d Biomarkers and molecular signatures that aid in the diag-
nosis of EoE
d Therapeutic/predictive accuracy of skin prick and patch
testing in patients with EoE
d Therapeutic value of dietary therapy in adults with EoE
d Natural history of EoE and rates and predictive indexes
of complications (food impaction, esophageal stricture,
and esophageal narrowing)
d Importance of treating asymptomatic patients with iso-
lated esophageal eosinophilia
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FIG E1. Endoscopic features of EoE. A, Normal esophagus. B, Esophageal furrowing. C, White mucosal
plaques. D, Esophageal ring trachealization. E, Small-caliber esophagus with mucosal tearing after
endoscopy.
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TABLE E1. Symptoms associated with EoE
Dysphagia and feeding dysfunction
Coping mechanisms: avoiding highly textured foods, such as meats, and bulky foods, such as bagels; cutting food in small pieces; lubricating foods before
eating with liquids or butter; extensive chewing of foods; washing food down with liquids; prolongation of mealtimes
Food impaction
Coping mechanisms: drinking liquid to wash food down, raising hands above head, jumping up and down, waiting for food to dissolve or to pass into
stomach
Chest pain
Coping mechanisms: avoiding foods or liquids that exacerbate pain, such as highly textured or bulky foods, alcohol, or acidic drinks
GERD-like symptoms recalcitrant to medical and surgical GERD management
Abdominal pain
Vomiting
Anorexia and early satiety
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TABLE E2. Endoscopic and radiologic features of EoE
Isolated stricture (proximal or distal)
Longitudinal narrowing (small or narrow-caliber esophagus)
Longitudinal shearing (crepe paper esophagus)
White exudates
Linear furrows or vertical lines
Fixed esophageal rings (corrugated rings or trachealization)
Transient esophageal rings (feline folds or felinization)
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TABLE E3. Histologic features of EoE
Mucosal eosinophilia
Eosinophil microabscess formation






Subepithelial fibrosis/sclerosis–lamina propria fibrosis
Mastocytosis and mast cell degranulation
CD81 lymphocytes and B cells
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